Is Sinovac good or not? What is the relationship between Sinovac Pharma and Sinovac Biotech

At present, Sinovac Pharmaceutical is a biopharmaceutical company, the company's business scale is growing year by year, and is now vigorously recruiting, if you are interested in Sinovac Pharmaceutical, you can try to submit your resume for an interview. Sinovac Pharmaceutical Co., Ltd. is an innovative biopharmaceutical company mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations.

Wait. In addition, the benefits and treatment of Sinovac Pharmaceutical are very good, including five insurances and one housing fund.

Holiday welfare, team building.

Welfare, etc., in Sinovac Pharmaceutical, you don't have to worry about your skills not growing, there are master classes, torch classes, and Whampoa.

class and so on to improve your ability, you also don't have to worry about not getting the opportunity to be promoted, in Sinovac Pharmaceutical, as long as there are vacancies, you can put forward your own needs, with your own efforts to fight, in the resources to excellent talents, so that talents are fully respected!

Is it Sinovac in Beijing? I went there a few years ago, the company's benefits and salaries are OK, but the management is stricter, you need to memorize the company's SOQ after entry, and then you can only work after passing the exam, there are more than a dozen people in the office, few people chat and talk, and the whole day is very quiet, no one pays attention to anyone, and I will feel more depressed when I work in it anyway.

Summary. Dear, Sinovac is no problem. Sinovac vaccine has indeed had the problem of bribery, and even went to the criminal ruling, but in fact, this is an incident a few years ago, for some reason, it was re-exposed after 5 years, I don't know what kind of psychology the publisher has, but this incident did cause a great degree of panic, Beijing Sinovac new crown inactivated vaccine has passed the WHO emergency use certification, and has also obtained a domestic new crown vaccine with conditional listing in China, Both Beijing Biotech and Beijing Sinovac have met the relevant technical standards of the World Health Organization and China's technical standards, and they can be vaccinated with Beijing Sinovac vaccine with confidence.

Dear, Sinovac is no problem. Sinovac vaccine has indeed had the problem of bribery, and even went to the criminal ruling, but in fact, this is an incident a few years ago, for some reason, it was re-exploded after 5 years, I don't know what kind of psychology the publisher has, but this incident did cause a very large degree of panic, Beijing Sinovac new crown inactivated vaccine is through the Chishu WHO emergency use recognition certificate, and in my country has also obtained a domestic new crown vaccine with conditional listing, Both Beijing Biotech and Beijing Sinovac have met the relevant technical standards of the World Health Organization and China's technical standards, and they can be vaccinated with Beijing Sinovac vaccine with confidence.

Dear, Beijing Kexing Biological Products is a joint venture between Sinovac Holdings (Hong Kong) and Beijing Peking University Weiming Bioengineering Group Co., Ltd. The company was registered in 2001 in Beijing Zhongguancun High-tech Air Search Park Peking University Biological City, the purpose of the establishment of the company: in line with the development of the high-tech industry in the sedan car Liguo biological sail bird engineering high-tech industry, the use of advanced scientific and technological achievements at home and abroad, and the introduction of international scientific management methods, human vaccine and related products research, production and sales, to provide technical advice and technical services, and then improve the level of prevention and treatment of a variety of serious diseases including hepatitis A and B at home and abroad, Contribute to human health.

1. Shenzhen Keyi Pharmaceutical Holdings****.

Shareholdings: 13,000 shares.

Shareholding ratio: 2. Shenzhen Hengjian Enterprise Management Partnership (Limited Partnership).

Shareholdings: 10,000 shares.

Shareholding ratio: 3. Shenzhen Yuzao Enterprise Management Partnership (Limited Partnership).

Shareholdings: 10,000 shares.

Shareholding ratio: 4. Changjiang Fortune Sinovac Pharmaceutical Employee Strategic Placement Collective Asset Management Plan.

Shareholdings: 10,000 shares.

Shareholding ratio: 5. China Securities Construction Investment ****.

Shareholdings: 10,000 shares.

Shareholding ratio: 6, Li Yonggang.

Shareholdings: 10,000 shares.

Shareholding ratio: 7. Tiansuan Quantitative (Beijing) Capital Management**** Tiansuan Exclusive No. 12 Private Placement **Investment**.

Shareholdings: 10,000 shares.

Shareholding ratio: 8, Wang Jianyu.

Shareholdings: 10,000 shares.

Shareholding ratio: 9. Shenzhen Runzeli Investment****.

Shareholdings: 10,000 shares.

Shareholding ratio: 10, Shu Jie.

Shareholdings: 10,000 shares.

There is no relationship, because the name has the word "Sinovac", and some people have confused Sinovac Pharmaceutical with Beijing vaccine company - Sinovac Holding Biotechnology **** (hereinafter referred to as "Sinovac"), in fact, the two have no relationship with each other.

Sinovac Pharmaceutical and Sinovac Biotech are not the same company, Sinovac Holding Biotechnology **** is a bio-high-tech enterprise headquartered in Beijing, currently listed on the NASDAQ Global Select Market in the United States, and the latest popular is his new crown vaccine. Sinovac Pharmaceutical is listed on the A-share Science and Technology Innovation Board, mainly producing recombinant human interferon, etc., which has nothing to do with vaccines.

1. Sinovac Pharmaceutical: It is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations, focusing on antiviral, tumor and immunity, blood, digestion, degenerative diseases and other fields.

2. Kexing Biotech: Kexing Biopharmaceutical Co., Ltd. (formerly known as: Shandong Kexing Biopharmaceutical Co., Ltd.), founded in 1997 and located in Jinan City, Shandong Province, is an enterprise mainly engaged in pharmaceutical manufacturing, with a registered capital of 10,000 yuan, more than 98% of its counterparts in Shandong Province, a paid-in capital of 10,000 yuan, and has completed a private placement in 2020.

Summary. The role of the Sinovac vaccine is also relevant data that everyone can see, and it also confirms that the Sinovac vaccine has rigorous safety data tracking in many countries around the world, all of which show that the Sinovac vaccine is safe, so the rumors stop at the wise. A follow-up survey of medical workers in China who received the Sinovac vaccine found that 96% of the vaccinated people were free from the death rate caused by the coronavirus, and 94% were free from hospitalization.

Hello dear. Sinovac vaccine does have a problem with bribery.

There has even been a criminal verdict, but in fact, this is an incident in which the previous years were suspended, and for some reason, it was re-exposed after 5 years, I don't know what kind of psychology the publisher has, but this incident did cause a lot of panic in the spring.

If there is, I believe that ** will also conduct a thorough investigation, so before the official results are announced, what we have to do is not to believe rumors, not to spread rumors.

It is understood that Beijing Sinovac Biotechnology **** developed Bixian's "inactivated vaccine", which was repented of being imitated by the country's strict quality inspection process and various matching, and also confirmed that the Sinovac new crown vaccine is safe, nationally certified, and has been listed as an emergency use list of the World Health Organization.

There are also a lot of rumors about Beijing Sinovac's illegal crimes, such as leukemia caused by Sinovac vaccination, measles after Sinovac vaccination, hair loss caused by Sinovac vaccine, tuberculosis, menstrual cessation in imaginary numbers, etc., in fact, Sinovac's new crown vaccine is the same as other Chinese vaccines such as Sinopharm, and it is also legal and compliant.

The role of the Sinovac vaccine is also a relevant number of evidence that everyone can see, and it also confirms that the Sinovac vaccine has strict and meticulous safety data tracking in many countries around the world, all of which show that the Sinovac vaccine is safe, so the rumors stop at the wise. A follow-up survey of medical workers in China who received the Sinovac vaccine found that 96% of the vaccinated people were free from the mortality caused by the coronavirus, and 94% were free from hospitalization.

Glad I had this question for you. Pro-Sinovac was hacked. 1. Sinovac's new crown vaccine was approved by the State Food and Drug Administration for conditional marketing in China as early as February 6, 2021, and it was only after a very strict R&D and quality inspection process that the safety was verified before large-scale vaccination was promoted in China.

Sinovac has been embroiled in controversy over layoffs, seizure of year-end bonuses, and reduction of severance compensation in recent years, but there is no doubt about safety. 3. It is not true that Sinovac was reported by his real name, and there is no official information that Kexing was reported. It is rumored on the Internet that some people reported Sinovac and its shareholders and management in real names, concealing the possibility that the Sinovac vaccine was only an experimental vaccine, allowing the recipients to get sick or dying, and concealing the data of illness and death, which is suspected of making a fortune in the country.

Sinovac's 2021 financial report shows that its operating income is as high as 128 billion yuan, and its net profit is 95.6 billion yuan. The top ten shareholders, except for the founder Yin Weidong, are all foreign-funded institutions. 4. Sinovac's real-name report is a rumor, and the so-called report content is not true.

Sinovac's safety and efficacy have been recognized by the WHO and countries around the world. Sinovac is a bio-high-tech enterprise jointly established by Sinovac Holdings, Beijing Peking University Weiming Brigade or Bioengineering Group Co., Ltd., and is not a state-owned enterprise, but Sinovac's main profits come from exports. If I found your answer helpful, please give it a thumbs up (rate it in the bottom left corner).

Beijing Sinovac has a clear shareholding structure, in which the Chinese minority shareholder Sui Stool Weiming Biotech holds the shares, and the foreign controlling shareholder Hong Kong Sinovac holds the shares. If calculated according to the so-called penetration of the unnamed party, Pan Aihua, Yang Xiaomin, Luo Shun, Zhao Furong and other 4 people indirectly hold the equity of Beijing Sinovac through the unnamed biological lead Chang. The board of directors of Sinovac is composed of 5 directors, of which 4 are appointed by Sinovac Hong Kong and 1 is appointed by Weiming Biotech.

The Board of Directors is the highest authority of Sinovac, and the Board of Directors decides all major matters of Sinovac. There are 7 items that must be unanimously approved by the Board of Directors, that is, each of the 5 members of the Board of Directors has the "right of veto" on these 7 items, but none of them has the "right to decide with one vote".

Sinovac Holding Biotechnology **** is a Beijing-based biopharmaceutical company, listed on the NASDAQ Global Select Market, and is a Chinese vaccine company listed in North America. In May 2022, Sinovac won the "2022 Global Partner of State-owned Enterprises Golden Rock Loss Award" by the Ministry of State-Owned Enterprises of Indonesia. The award aims to thank the enterprises that have cooperated with the Indonesian enterprise Huaiwu Chop Industry and made outstanding contributions in various aspects.

As a biopharmaceutical company, Sinovac's customers can include various types of businesses and institutions. Under the stool hole are some of the types of businesses that may become customers of Sinovac: 1

Medical facilities: Medical institutions including hospitals, clinics, vaccination sites, etc., may be Sinovac customers, as Sinovac produces and supplies medical products such as vaccines. 2.

Institutions: Health authorities, public health agencies, centers for disease control, etc., may have partnerships with Sinovac to purchase or use vaccines and other medicines they produce. 3.

Pharmaceutical Distributors and Distributors: Pharmaceutical distributors and distributors may work with Sinovac Pharmaceutical to help distribute and sell Sinovac's products to various markets and sales channels. 4.

International organizations and non-profit organizations: International health organizations, non-profit organizations, charities, etc., may partner with Sinovac to meet public health needs, such as vaccination programs, emergency relief programs, etc.

Sinovac's largest shareholder is Sinovac (Hong Kong).

Beijing Sinovac Biological Products is a bio-high-tech enterprise jointly established by Sinovac Holdings (Hong Kong) and Beijing Peking University Weiming Bioengineering Group Co., Ltd. The company was registered and established in 2001 in Peking University Bio-City, Zhongguancun High-tech Park, Beijing. The purpose of the company's formation and operation:

In line with the desire to develop China's high-tech industry in the early stage of bioengineering, we adopt advanced scientific and technological achievements at home and abroad, and introduce international scientific management methods to carry out research, production and sales of human vaccines and related products, provide technical advice and technical services, and then improve the level of prevention and treatment of a variety of serious diseases including hepatitis A and B at home and abroad, and contribute to human health.

Extended Information] Sinovac Holdings is the first vaccine company in China to be listed in the United States, and through its Hong Kong branch, it holds a stake in Beijing Sinovac Biological Products. Beijing Sinovac Holding Co., Ltd. also has a wholly-owned subsidiary in Tangshan, Hebei Province - Tangshan Yion Bioengineering, which is dedicated to the research and development of veterinary vaccines. On November 4, 2009, Beijing Sinovac Holding Co., Ltd. announced that the company successfully transferred to the NASDAQ global market, and it is expected that it will be officially listed on the NASDAQ exchange in mid-November, and the trading ** is SVA.

Previously, Beijing Sinovac Holdings Co., Ltd. was listed on the ** Exchange in the United States (AMEX).

Beijing Kexing has built a professional R&D and management system, forming a R&D model with enterprises as the main body of R&D and a combination of production, education and research. It has successful experience in the research and development of new vaccines and a technical team, adheres to independent innovation to create core competitiveness, adopts advanced technology to continuously develop new vaccines, and carries out technological transformation of traditional vaccines. The research and development of Beijing Sinovac has been strongly supported, and has carried out extensive cooperation with famous universities and research institutes at home and abroad.

Beijing Sinovac has undertaken including:"SARS inactivated vaccine development"、"Broad-spectrum influenza pandemic vaccines"and other National High-tech Research and Development Program (863 Program) projects"Avian influenza vaccine for human use"He has researched more than 20 scientific research projects, including the national science and technology research project Lu Yin, the national science and technology major project, the national high-tech industrialization demonstration project, the national high-tech industrialization project and the Beijing major special project, and has successfully realized the industrialization of a number of scientific and technological achievements. When people are looking forward to using vaccines to control the disease, Beijing Sinovac has stepped forward.